Medical devices, healthcare technology and the business of care
510(k) clearance · K262109

Access NT-proBNP

BECKMAN COULTER, INC. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONK262109

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K262109, the Access NT-proBNP assay from Beckman Coulter, Inc., on September 21, 2026, with the submission received June 23, 2026. The device is a Class II B-type natriuretic peptide test system under 21 CFR 862.1117, product code NBC, in the Clinical Chemistry specialty. A 510(k) clearance is not a PMA approval.

The cleared item is a paramagnetic particle, chemiluminescent sandwich immunoassay for quantitative N-terminal pro B-type natriuretic peptide in human serum and plasma on automated Access Immunoassay Analyzers. The comparison table lists the candidate as Access NT-proBNP on the Access 2 Immunoassay System and the predicate as Access NT-proBNP on the DxI 9000 Immunoassay Analyzer (K232164), with the analyzer pairing marked as the difference. The source does not state performance study results or the basis for the SESE determination.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Sep 21, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262109
Regulatory pathway
510(k) premarket notification
Product code
NBC
Decision code
SESE
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, Natriuretic Peptide.

Product code
NBC
FDA device class
2

FDA decision timeline

  1. K262109 received

    Application receipt date recorded by FDA.

  2. K262109 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NBC

Product / regulatory recordCompanyPathwayDecision dateSource
BECKMAN COULTER, INC.510(k) clearanceOct 20, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

BECKMAN COULTER, INC.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Chaska, MN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records